RxDoctor Payments Data

Aaron Holley, MD

Pulmonary Disease · Bethesda, MDNPI 1750485439

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (60.0%), grants and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by GSK at 60.0% of the total. Reporting peaked in 2020 at $2,000 and has fallen 90.4% since, to $191 in 2025.

$3,334in general payments, 2019–2025

Across 27 payments — averaging $123.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Genentech, Inc.$1K
  • Shionogi Inc$168
  • AstraZeneca$76
  • Mallinckrodt Hospital Products Inc.$28
  • Inspire Medical Systems, Inc.$25
  • plus $37 from 2 others
$69,554in research payments, 2019–2025

Across 19 payments — averaging $3660.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$44K
  • GSK$26K

What the payments were for

  • Consulting fees$2,00060%
  • Grants$1,00030%
  • Food & beverage$1665%
  • Education$1685%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,334 in reported general payments places this provider in the 65th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Medicare billing

Part B allowed, 2024
$84,809
Medicare patients
360
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab12$44,496
Spiriva RespimatTiotropium Bromide21$18,348
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,776
SymbicortBudesonide/Formoterol Fumarate19$7,281
Advair HfaFluticasone Propion/Salmeterol16$5,778
Albuterol Sulfate HfaAlbuterol Sulfate62$1,877
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,504
Wixela InhubFluticasone Propion/Salmeterol11$1,135
Fluticasone Propionate19$461
Zolpidem Tartrate18$271
Prednisone31$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta$2,000$60,27228 claims
AstraZenecaSymbicort$76$7,28119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 297 pulmonary disease providers in Maryland.

Other pulmonary disease in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →